We sought to determine the long-term (median follow-up, 7.5 years) predictive power of human MutS homologue 2 (MSH2) immunohistochemical expression in patients who enrolled in the International Adjuvant Lung Trial. Experimental design: We tested the interaction between MSH2 and the allocated treatment (chemotherapy versus observation) in a Cox model adjusted on clinicopathologic variables. The significance level was set at 0.01.
Department of Medicine, Biostatistics and Epidemiology Unit, Translational Research Laboratory, Paris-Sud University, Gustave-Roussy Institute, Villejuif, France.
